Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina I Herold

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Breast (Edinburgh, Scotland)|February 19, 2008
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancerChristina I Herold, Kimberly L Blackwell
Clinical Breast Cancer|May 27, 2008
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of diseaseChristina I Herold, Kimberly L Blackwell
Cancer Investigation|December 19, 2008
Primary systemic therapy in breast cancer: past lessons and new approachesChristina I Herold, P Kelly Marcom
Oncology (Williston Park, N.Y.)|November 29, 2013
New targets for triple-negative breast cancerChristina I Herold, Carey K Anders
Case Reports in Hematology|September 1, 2012
Lenalidomide-Associated ITPChristina I Herold, Cristina Gasparetto, Gowthami M Arepally
Breast Cancer Research and Treatment|October 7, 2009
Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancerChristina I Herold, Benjamin Djulbegovic, Iztok Hozo, et al.
Clinical Breast Cancer|August 9, 2011
Second primary ipsilateral breast cancer with contralateral axillary involvement: a case report and literature reviewChristina I Herold, Elizabeth M Gaughan, Carolyn C Lamb, et al.
Annals of Surgical Oncology|July 2, 2016
Early-Stage Breast Cancer in the Octogenarian: Tumor Characteristics, Treatment Choices, and Clinical OutcomesAnita Mamtani, Julie J Gonzalez, Dayna Neo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2011
Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosingChristina I Herold, Vijaya Chadaram, Bercedis L Peterson, et al.
Molecular Cancer Research : MCR|June 14, 2011
Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markersAndrew J Armstrong, Matthew S Marengo, Sebastian Oltean, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Breast (Edinburgh, Scotland)|February 19, 2008
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancerChristina I Herold, Kimberly L Blackwell
Clinical Breast Cancer|May 27, 2008
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of diseaseChristina I Herold, Kimberly L Blackwell
Cancer Investigation|December 19, 2008
Primary systemic therapy in breast cancer: past lessons and new approachesChristina I Herold, P Kelly Marcom
Oncology (Williston Park, N.Y.)|November 29, 2013
New targets for triple-negative breast cancerChristina I Herold, Carey K Anders
Case Reports in Hematology|September 1, 2012
Lenalidomide-Associated ITPChristina I Herold, Cristina Gasparetto, Gowthami M Arepally
Breast Cancer Research and Treatment|October 7, 2009
Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancerChristina I Herold, Benjamin Djulbegovic, Iztok Hozo, et al.
Clinical Breast Cancer|August 9, 2011
Second primary ipsilateral breast cancer with contralateral axillary involvement: a case report and literature reviewChristina I Herold, Elizabeth M Gaughan, Carolyn C Lamb, et al.
Annals of Surgical Oncology|July 2, 2016
Early-Stage Breast Cancer in the Octogenarian: Tumor Characteristics, Treatment Choices, and Clinical OutcomesAnita Mamtani, Julie J Gonzalez, Dayna Neo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2011
Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosingChristina I Herold, Vijaya Chadaram, Bercedis L Peterson, et al.
Molecular Cancer Research : MCR|June 14, 2011
Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markersAndrew J Armstrong, Matthew S Marengo, Sebastian Oltean, et al.
Pageof 2